Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Monday 29 October, 2007

XTL Biopharm Ltd

XTL to Present at the Rodman & Renshaw Heal...

  XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health  
                                Care Conference                                

VALLEY COTTAGE, NEW YORK, October 29, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the
Company's Chief Executive Officer, is scheduled to present at the Acumen BioFin
Rodman & Renshaw 9th Annual Health Care Conference. Mr. Bentsur will present an
overview of the Company including a discussion of Bicifadine, the Company's
late-stage clinical compound for the treatment of neuropathic pain. Mr.
Bentsur's presentation will take place on Monday, November 5, 2007 at 8:50 am
EST at the New York Palace Hotel in New York City.

A live webcast of the presentation will be available at:                                         

An archived version of the webcast will be available following the conclusion 
of the live presentation.


XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is
developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for
the treatment of diabetic neuropathic pain. XTL is also developing several
novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an
active in-licensing and acquisition program designed to identify and acquire
additional drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).


Ron Bentsur, Chief Executive Officer

Tel: +1-(845)-267-0707 ext. 225


a d v e r t i s e m e n t